Amyotrophic Lateral Sclerosis Clinical Trial
— ALSDPEGOfficial title:
Dysphagia, Quality of Life and Attitudes Towards Percutaneous Endoscopic Gastrostomy in Patients With Amyotrophic Lateral Sclerosis
NCT number | NCT05336760 |
Other study ID # | URIS202201 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | January 1, 2023 |
Est. completion date | March 31, 2026 |
In Amyotrophic Lateral Sclerosis, dysphagia has a high incidence. With deterioration of swallowing function, percutaneous endoscopic gastrostomy (PEG) tube is recommended to ensure sufficient and safe oral intake. Dysphagia and PEG placement alter quality of life (QoL). However, QoL and attitudes toward PEG remain largely unexplored. The purpose of this study is to monitor the swallowing function in relationship to QoL and attitudes toward PEG tube insertion and feeding.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | March 31, 2026 |
Est. primary completion date | March 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for patients: - 18 years of age or older - diagnosis of ALS - follow-up at University Medical Centre Ljubljana, Division of Neurophysiology, every 3 months - be able to visit the study site for in-person procedures every 3 months Inclusion Criteria for relatives: - at least 18 years of age Exclusion Criteria for patients: - co-existing illness or disorder that could influence the swallowing function independently of the ALS diagnosis - clinically significant cognitive deterioration or dementia at enrollment, as determined by the ALS study neurologist Exclusion criteria for relatives: - signs of probable cognitive deterioration or dementia at enrollment |
Country | Name | City | State |
---|---|---|---|
Slovenia | University Medical Centre Ljubljana | Ljubljana |
Lead Sponsor | Collaborator |
---|---|
University Rehabilitation Institute, Republic of Slovenia | University Medical Centre Ljubljana |
Slovenia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Penetration-Aspiration Scale (PAS) change | PAS is an 8-point scale used to determine swallowing safety. Levels 1 and 2 are considered safe, levels >3 indicate penetration or aspiration and are considered unsafe. | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Primary | Yale Residue Severity Rating Scale (YRSRS) change | YRSRS is a validated measure of swallowing efficiency using an image-based assessment to determine post-swallow pharyngeal residue: location and severity. It is assessed using a 5-point ordinal scale (from 1=0 % residue to 5=50 % residue). | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Primary | Iowa Oral Performance Instrument (IOPI) change | IOPI is a device which measures tongue strength (in kilopascals; kPa) and endurance (in seconds) while the participant presses the bulb with the front or the base of their tongue to the hard palate. | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Primary | Mann Assessment of Swallowing Ability (MASA) change | MASA is a standard clinical swallowing assessment protocol administered by the speech-language therapist. Total score ranges from 38-200. Lower score indicates higher impairment. | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Primary | Eating Assessment Tool 10 (EAT-10) change | EAT-10 is a validated self-administered dysphagia severity symptom survey including 10 items and a five-point scale (0=no problem to 4=sever problem). Higher total score indicates higher impairment. | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Primary | Swallowing Quality of Life Questionnaire (SWAL-QoL) change | SWAL-QoL is a 44-item standardised psychometric scale that measures swallowing-related QoL across 10 domains. Scores for each individual domain and a total SWAL-QoL score are calculated. Total score ranges from 0-100 (100 indicating the most favourable state). | At baseline and every 3 months until PEG insertion, 3 and 6 months after PEG insertion | |
Primary | Questionnaire on Attitudes Toward PEG Tube Feeding and Insertion Procedure change | The questionnaire comprises 10 questions. The participants specify their level of agreement on a five-point Likert-type scale (1=strongly disagree, 5= strongly agree). | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | ALS Functional Rating Scale-Revised (ALSFRS-R) change | ALSFRS-R is a 12-tem ALS-specific assessment of global functioning using a five-point scale (0=not able, 4= normal ability), with 48 points representing normal function. | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | Functional Oral Intake Scale (FOIS) change | FOIS is a validated 7-point scale demonstrating an individual's ability of daily oral food intake (1=no oral intake, 7=total oral intake with no restrictions). | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | Dysphagia Outcome and Severity Scale (DOSS) change | DOSS is a 7-point scale that rates the functional severity of dysphagia based on objective assessment and provides information on diet recommendations, independence level and type of nutrition necessary (level 7=normal swallowing function, level 1=severe dysphagia). | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | BMI change | Body mass index (in kg/m^2) | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | Forced Vital Capacity (FVC) change | Standard clinical respiratory assessment of FVC (in %) | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | Peak Cough Flow (PCF) change | Standard clinical respiratory assessment of PCF (in L/min) | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | Maximal Inspiratory Pressure (MIP) change | Standard clinical respiratory assessment of MIP (in cmH2) | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) | |
Secondary | Maximal Expiratory Pressure (MEP) change | Standard clinical respiratory assessment of MEP (in cmH2) | Difference between baseline and PEG insertion (usually in 6-25 months after diagnosis, maximum follow-up 30 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04428775 -
A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
|
Phase 2 | |
Recruiting |
NCT04998305 -
TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
|
Phase 1/Phase 2 | |
Recruiting |
NCT05951556 -
Telehealth Implementation of Brain-Computer Interface
|
N/A | |
Terminated |
NCT04579666 -
MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT04082832 -
CuATSM Compared With Placebo for Treatment of ALS/MND
|
Phase 2/Phase 3 | |
Completed |
NCT01925196 -
Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation
|
||
Completed |
NCT02496767 -
Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year
|
Phase 3 | |
Recruiting |
NCT04816227 -
Expression Profile Study of Macrophages From Patients Affected by ALS or Other Related Motor Impairments
|
||
Active, not recruiting |
NCT04494256 -
A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation
|
Phase 1/Phase 2 | |
Completed |
NCT03706391 -
Study of ALS Reversals 4: LifeTime Exposures
|
||
Recruiting |
NCT04882904 -
Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.
|
N/A | |
Completed |
NCT04557410 -
Open Label Study: Treatment of ALS Fatigue With PolyMVA
|
Phase 1 | |
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04089696 -
Validation of the "ExSpiron©" in Patients With ALS
|
N/A | |
Not yet recruiting |
NCT05860244 -
Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients
|
Phase 2 | |
Not yet recruiting |
NCT06450691 -
Modeling Amyotrophic Lateral Sclerosis With Fibroblasts
|
N/A | |
Not yet recruiting |
NCT04220190 -
RAPA-501 Therapy for ALS
|
Phase 2/Phase 3 | |
Recruiting |
NCT02917681 -
Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03067857 -
Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT02874209 -
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
|
N/A |